EVALUATING THE IMPACT AND HEMATOLOGICAL ASSESSMENT OF TENOFOVIR WITH MELISSA OFFICINALIS EXTRACT IN DECOMPENSATED CHRONIC LIVER DISEASE PATIENTS WITH HEPATITIS:A CROSS-SECTIONAL STUDY
Main Article Content
Keywords
Chronic hepatitis B, cirrhosis, Hepatic decompensation, Antiviral therapy, Tenofovir, Melissa officinalis
Abstract
Background: Chronic hepatitis B (CHB) and decompensated chronic liver disease (DCLD) pose substantial global health challenges, often leading to severe liver dysfunction and potentially life-threatening complications. Hepatic decompensation, characterized by the liver's inability to perform its essential functions, is a critical consequence of CHB and DCLD, underscoring the need for effective management strategies.
Objectives: To determine the effectiveness of antiviral drug tenofovir with Melissa officinalis in preventing hepatic decompensation in patients with chronic hepatitis B and decompensated cirrhosis. Duration and Place of Study: The study was conducted between August 2023 and July 2024 at the Department of Gastroenterology in Dow university of Health sciences.
Methodology: A comprehensive study involving 191 patients with chronic hepatitis B and decompensated cirrhosis compared the efficacy of two antiviral therapies, Tenofovir and Melissa officinalis leaves extract in preventing hepatic decompensation episodes. These episodes include severe complications such as ascites, variceal bleeding, hepatic encephalopathy and spontaneous bacterial peritonitis. The study collected detailed demographic, clinical and laboratory data to assess liver function and disease severity. By evaluating the effectiveness of these treatments, the study aimed to inform optimal management strategies for patients with chronic hepatitis B and decompensated cirrhosis, ultimately improving clinical decision-making and patient outcomes. Results: The study found that antiviral treatment was effective in preventing hepatic decompensation in 60.2% of patients. Tenofovir demonstrated superior efficacy (76.4%) as compared to Melissa officinalis (53.7%) (p=0.004). Significant predictors of efficacy included INR levels (Exp(B)=0.208, p=0.014) and the type of treatment (Tenofovir vs Melissa officinalis) (Exp(B)=2.432, p=0.022). Conclusion: Antiviral therapy, Tenofovir in particular, can effectively reduce hepatic decompensation in cirrhotic and HBV-related chronic hepatitis B infection patients. INR is a key predictive indicator for successful therapy.
References
2. Zhang YY, Meng ZJ. Definition and classification of acute-on-chronic liver diseases. World J Clin Cases. 2022;10(15):4717-4725. doi: 10.12998/wjcc.v10.i15.4717
3. Rizzo GEM, Cabibbo G, Craxì A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses. 2022;14(5):986. doi: 10.3390/v14050986
4. Moreno C, Qi X. Evolution in diagnosis and management of chronic liver diseases. United European Gastroenterol J. 2023;11(10):945-947. doi: 10.1002/ueg2.12502
5. Rajpurohit S, Musunuri B, Shailesh, Basthi Mohan P, Shetty S. Novel drugs for the management of hepatic encephalopathy: still a long journey to travel. J Clin Exp Hepatol. 2022;12(4):12001214.
6. Park H, Jiang X, Song HJ, Lo Re V 3rd, Childs-Kean LM, Lo-Ciganic WH, et al. The Impact of direct-acting antiviral therapy on end-stage liver disease among individuals with chronic hepatitis C and substance use disorders. Hepatology. 2021;74(2):566-581. doi: 10.1002/hep.31732
7. Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol. 2021;27(29):4831-4845. doi: 10.3748/wjg.v27.i29.4831
8. Sharma P, Sawtell R, Wang Q, Sise ME. Management of hepatitis C virus and hepatitis B virus infection in the setting of kidney disease. Adv Kidney Dis Health. 2023;30(4):343-355.
9. Nakamura A, Yoshimura T, Ichikawa T. A Case of hepatitis C-related decompensated cirrhosis observed by MRI imaging data during treatment with direct-acting antiviral agents. Cureus. 2021;13(10):e19001. doi: 10.7759/cureus.19001
10. Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: the pursuit of a functional cure. World J Gastroenterol. 2021;27(21):2727-2757.
11. Premkumar M, Anand AC. Overview of complications in cirrhosis. J Clin Exp Hepatol. 2022;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021
12. Sharma P. Value of liver function tests in cirrhosis. J Clin Exp Hepatol. 2022;12(3):948-964.
13. Saracco GM, Marzano A, Rizzetto M. Therapy of chronic viral hepatitis: the light at the end of the tunnel? Biomedicines. 2022;10(3):534. doi: 10.3390/biomedicines10030534
14. Miquel M, Núñez Ó, Trapero-Marugán M, Díaz-Sánchez A, Jiménez M, Arenas J, et al. Efficacy and safety of Melissa officinalis and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol. 2013;12(2):205-12.
15. Jang JW, Choi JY, Kim YS. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2018;16(12):1954-1963. doi: 10.1016/j.cgh.2018.04.063
16. Herrington CS, Coates PJ, Duprex WP. Viruses and disease: emerging concepts for prevention, diagnosis and treatment. J Pathol. 2015;235:149-152.
17. Carrillo-Infante C, Abbadessa G, Bagella L, Giordano A. Viral infections as a cause of cancer (review). Int J Oncol. 2007;30:1521-1528.
18. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2020;92:1875-1883.
19. Boban M. Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract. 2021;75:e13868.
20. De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29:695-747.
21. Dyrka K, Miedziaszczyk M, Szałek E, Łącka K. Endocrine abnormalities induced by the antiviral drugs and frequency of their occurrence. Pol Merkur Lekarski. 2020;48:209-214.
22. Zareifopoulos N, Lagadinou M, Karela A, Kyriakopoulou O, Velissaris D. Neuropsychiatric effects of antiviral drugs. Cureus. 2020;12:e9536.
23. Leowattana W. Antiviral drugs and acute kidney injury (AKI). Infect Disord Drug Targets. 2019;19:375-382.
24. Lee JY, Abundo MEC, Lee CW. Herbal medicines with antiviral activity against the influenza virus, a systematic review. Am J Chin Med. 2018;46:1663-1700.
25. Astani A, Navid MH, Schnitzler P. Attachment and penetration of acyclovirresistant herpes simplex virus are inhibited by Melissa officinalis extract. Phytother Res. 2014;28:1547-1552.
26. Miraj S, Rafieian-Kopaei M, Kiani S. Melissa officinalis L: a review study with an antioxidant prospective. J Evid Base Compl Altern Med. 2016;22:385-394.
27. ElhamKia M, Setayesh L, Yarizadeh H, et al. The interaction between dietary total antioxidant capacity and MC4R gene and HOMA-IR in metabolically healthy and unhealthy overweight and obese women. Nutr Metab Insights. 2022;15:11786388221105984.
28. Hosseinifard E-S, Bavafa-Valenlia K, Saghafi-Asl M, Morshedi M. Antioxidative and metabolic effects of Lactobacillus plantarum, inulin, and their synbiotic on the hypothalamus and serum of healthy rats. Nutr Metab Insights. 2020;13: 1178638820925092
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sonia khan
Associate Professor, Dept of Pharmacology, Al-Tibri Medical College, Karachi, Pakistan
Tazeen Burhan
Family physician Prime Medical centre , Ajman ,UAE
Huma Tariq
Staff Pathologist ,Dept of Pathology and Laboratory Medicine, Aga khan university hospital
Madiha
Consultant Hematologist, Afzaal memorial thalassemia foundation, Karachi, Pakistan
Waqas Manzoor
Assistant Professor Gastroenterology ,Al Tibri medical college & hospital, Karachi, Pakistan
Saima Siddiqui
Lecturer, Dept of Pharmacology, Al-Tibri Medical College, Karachi, Pakistan
Farooq Ahmed
Final year MBBS student, Al-Tibri Medical College, Karach
Muhammad Ashraf
Family physician & Diabetologist, Al-Rahim Clinic FB Area Hussain Abad, Karachi, Pakistan
Rizwan Ali
Medical Officer ,THQ Hospital Ghotki, Sindh , Pakistan
Mehjabeen
Professor, Dept of Pharmacology, Federal Urdu university of arts science and technology, Karachi, Pakistan
Misha Fatima
First Year, Pre –Medical student, karachi, Pakistan